Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6

Trial Profile

Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Nov 2014

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 30 Sep 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Feb 2013 Planned number of patients changed from 350 to 500 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top